drugset / Trial / NCT00931723

Adult Bipolar Mania

NCT00931723

Phase 4 Completed 356 enrolled AstraZeneca Quintiles, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it compares with placebo (a non-active capsule, like a sugar pill, that looks like lithium).

Timeline

Start
2009-06
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lithium Unknown 900 mg Oral
Comparator Quetiapine Small molecule 600 mg Oral